Merck’s Keytruda (pembrolizumab) received a rejection from the U.S. Food and Drug Administration for each of six supplemental Biologics License Applications to update the dosing frequency of the checkpoint inhibitor to include every-six-weeks administration.
Frank Reynolds, the founder and former chief executive officer of PixarBio, was sentenced to seven years in prison for defrauding investors.
Hector Armando Kellum, a former senior executive with the Novartis subsidiary Sandoz, pleaded guilty for his role in a price-fixing scheme for generic drugs developed by his company.
Intellia Therapeutics is focused on implementing a full-spectrum genome editing approach, as the company has a pipeline spanning both in vivo and ex vivo therapies to address severe and life-threatening diseases.
Fingerpaint – a full-service health and wellness marketing agency with offices in New York, Pennsylvania, Arizona, New Jersey and California – announced that Michelle Petroff was promoted to lead the Conshohocken, Pa., office.
Astellas company Audentes Therapeutics announced construction of a gene therapy manufacturing plant in Sanford, North Carolina.
